Merck & Co. Inc. is still deciding whether to file anacetrapib after the presentation of full data from the four-year, 30,000-patient REVEAL study at the European Society of Cardiology meeting in Barcelona on Aug. 29 showed it reduced the risk of major coronary events in high risk patients by a modest 9% compared with placebo, when used on top of intensive statin therapy.
REVEAL: Limited Benefit Leaves Merck & Co Still Undecided On Anacetrapib's Future
The commercial future of Merck & Co's CETP inhibitor anacetrapib is still in limbo as the 9% reduction in the risk of CV events seen in REVEAL underwhelms. Filings look unlikely.
